STERIS (STE) Q1 2027 earnings review
Steady Top-Line Growth, but Strategic Restructuring Squeezes Free Cash Flow
STERIS delivered a highly predictable 'beat and raise' algorithm, but this quarter featured a twist. While revenue grew a stable 7% and adjusted EPS accelerated by 11% to $2.59, free cash flow reversed course. Net cash from operations fell YoY, dragged down by working capital requirements. To fuel long-term capacity, management announced a $55-$70M restructuring plan to consolidate U.S. chemistries into a new North Carolina Center of Excellence, pushing FY27 CapEx up by $75M and lowering the full-year free cash flow guide to $800M. The core business remains incredibly resilient, but the cash flow dynamics require monitoring.
🐂 Bull Case
Healthcare service revenue (+10%) and consumables (+9%) continue to provide a high-margin, recession-resistant baseline that effortlessly offsets pockets of capital equipment lumpiness.
Life Sciences capital equipment surged 17% YoY, confirming that the extended post-COVID pharma spending trough is firmly in the rearview mirror.
🐻 Bear Case
Despite Net Income rising by $22M YoY, Operating Cash Flow fell by $53M. If inventory and receivables remain elevated, it restricts the cash available for their newly authorized $1B buyback program.
AST capital equipment plummeted 13%, highlighting continued volatility and tough comps in the medtech customer base.
⚖️ Verdict: ⚪
Neutral to Bullish. The core business is executing flawlessly with stable 6-7% organic growth. However, the unexpected downgrade in free cash flow guidance—even for a positive reason like capacity expansion—moderates near-term excitement.
Key Themes
Healthcare Services & Consumables Anchoring Growth
The Healthcare segment (70% of total revenue) grew a robust 8% organically, led by a 10% jump in services and 9% in consumables. Capital equipment in this segment was stable (+1%). Hospitals are treating sterilization infrastructure as a utility—essential spending that cannot be deferred, allowing STERIS to successfully push pricing through to offset inflation.
Life Sciences Capital Expenditures Rebounding
Accelerating. Following an 18-month cyclical trough heavily discussed in FY26, Life Sciences capital equipment revenue spiked 17% in Q1. Consumables (+8%) and services (+2%) rounded out a solid 9% reported growth quarter for the segment. Reshoring of aseptic manufacturing to the US continues to act as a structural tailwind for this division.
Working Capital Drag Sinks Operating Cash Flow
A clear contradiction to the positive earnings narrative: Q1 Net Income rose $23M YoY, but Operating Cash Flow decelerated violently, dropping from $420M to $367.1M. Management attributed this directly to a 'significantly lower contribution from working capital.' Investors need to watch accounts receivable ($1.01B) and inventory ($712M) balances closely, as inefficient working capital management threatens the funding of the new $1B share repurchase program.
Manufacturing Optimization via North Carolina Expansion
STERIS is initiating a targeted $55-$70M restructuring plan to close chemistry plants in St. Louis and Plymouth, shifting production to a new formulated chemistries 'Center of Excellence' in North Carolina. While this drives CapEx up near-term, it aligns with management's broader push toward automation and innovation to expand long-term US chemistries capacity.
AST Segment Volatility Persists
While AST service revenue grew a steady 6%, AST capital equipment dropped sharply by 13%. Management previously warned of tough comps and medtech customer inventory adjustments carrying into H1 FY27. This lumpiness makes AST the most vulnerable segment in the near term.
Tariff and Inflation Realities
Operating income gains across Healthcare and Life Sciences were explicitly cited as being 'somewhat offset by inflation and increased tariff costs.' While STERIS has demonstrated pricing power, the persistent drag from raw material tariffs and labor inflation limits the ceiling on margin expansion.
Stable Macro Despite Complexities
CEO Dan Carestio highlighted 'stable underlying demand' as hospitals and pharma customers navigate a 'complex operating environment.' Unlike heavily consumer-exposed peers, STERIS's essential infection prevention products shelter it from broader macroeconomic interest-rate sensitivities.
Other KPIs
Stable. AST Operating Income rose to $142.9M from $136.7M a year ago. Despite the 13% drop in capital equipment, better pricing power allowed the segment to absorb increased depreciation and labor costs without sacrificing profitability.
Decelerating. Down from $326.5M in Q1 FY26. While CapEx was slightly lower YoY ($87.5M vs $93.6M), the steep drop in operating cash flows ($367.1M vs $420.0M) due to working capital timing drove the FCF decline.
Accelerating. Up from $235.5M last year. The segment benefited from improved volume, price, productivity, and favorable mix, which comfortably outpaced the headwinds from inflation and tariffs.
Guidance
Stable. Reiterated previous guidance, implying constant currency organic growth of 6% to 7%. This reflects confidence in the recurring revenue base and a continued Life Sciences recovery.
Stable. Guidance reiterated. At the midpoint ($11.20), this represents a 10% YoY increase from FY26's $10.17, highlighting excellent operational leverage despite external cost pressures.
Decelerating. Lowered from prior expectations of $850 million. The $50M reduction is entirely driven by higher anticipated capital expenditures to build the new North Carolina facility, partially offset by Q1 cash flows.
Accelerating. Raised significantly from previous expectations of $375 million to accommodate the strategic manufacturing consolidation in North Carolina.
Key Questions
Working Capital Dynamics
What specific factors drove the significantly lower contribution from working capital in Q1, and how quickly do you expect inventory and receivables to normalize in FY27?
Restructuring Nuance
You previously announced a $60M Mentor, Ohio plant. With the new Formulated Chemistries Center of Excellence in North Carolina, how does the total US manufacturing footprint look, and are there more facility consolidations planned?
AST Capital Equipment
AST capital equipment dropped 13% this quarter. Are you seeing deferred purchasing behavior from MedTech customers, or is this strictly a difficult year-over-year comparison playing out as expected?
Capital Allocation Timing
Given the higher CapEx requirement and lower FCF guide, does this delay or alter the cadence of the $200-$300M annual run rate you targeted under the new $1B share repurchase authorization?